MENLO PARK, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Corcept Therapeutics Incorporated today announced that the company will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Wednesday, November 9th, at 9:25 a.m. (EST) at the New York Palace Hotel. The presentation will cover the company’s clinical and corporate progress.
A live and subsequent archive of the Corcept presentation will be available on November 9, 2005 via webcast at: http://wsw.com/webcast/rrshq7/cort
The webcast will be available for 2 weeks.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Corcept’s lead product, CORLUX(R), is currently in Phase III clinical trials for the treatment of the psychotic features of psychotic major depression (PMD). The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. For additional information about the company, please visit www.corcept.com.
Corcept Therapeutics Incorporated
CONTACT: Fred Kurland, Chief Financial Officer of Corcept Therapeutics,+1-650-327-3270 or IR@corcept.com
Web site: http://www.corcept.com/
